BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 11707007)

  • 1. Comparative efficacy and safety study of etidronate and alendronate in postmenopausal osteoporosis. effect of adding hormone replacement therapy.
    Cortet B; Béra-Louville A; Gauthier P; Gauthier A; Marchandise X; Delcambre B
    Joint Bone Spine; 2001 Oct; 68(5):410-5. PubMed ID: 11707007
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A four-year randomized controlled trial of hormone replacement and bisphosphonate, alone or in combination, in women with postmenopausal osteoporosis.
    Wimalawansa SJ
    Am J Med; 1998 Mar; 104(3):219-26. PubMed ID: 9552083
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early response to alendronate after treatment with etidronate in postmenopausal women with osteoporosis.
    Iwamoto J; Takeda T; Ichimura S; Uzawa M
    Keio J Med; 2003 Jun; 52(2):113-9. PubMed ID: 12862363
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of alendronate combined with hormone replacement therapy on osteoporotic postmenopausal Chinese women.
    Tseng LN; Sheu WH; Ho ES; Lan HH; Hu CC; Kao CH
    Metabolism; 2006 Jun; 55(6):741-7. PubMed ID: 16713432
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comparison of continuous alendronate, cyclical alendronate and cyclical etidronate with calcitriol in the treatment of postmenopausal vertebral osteoporosis: a randomized controlled trial.
    Sahota O; Fowler I; Blackwell PJ; Lawson N; Cawte SA; San P; Masud T; Hosking DJ
    Osteoporos Int; 2000; 11(11):959-66. PubMed ID: 11193249
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alendronate increases spine and hip bone mineral density in women with postmenopausal osteoporosis who failed to respond to intermittent cyclical etidronate.
    Watts NB; Becker P
    Bone; 1999 Jan; 24(1):65-8. PubMed ID: 9916786
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of effect of treatment with etidronate and alendronate on lumbar bone mineral density in elderly women with osteoporosis.
    Iwamoto J; Takeda T; Sato Y; Uzawa M
    Yonsei Med J; 2005 Dec; 46(6):750-8. PubMed ID: 16385649
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Are oral bisphosphonates effective in improving lumbar bone mineral density in breast cancer survivors with osteopenia or osteoporosis?
    Sawka AM; Ioannidis G; Papaioannou A; Thabane L; Olszynski WP; Brown JP; Hanley DA; Murray TM; Josse RG; Sebaldt RJ; Petrie A; Tenenhouse A; Goldsmith CH; Boulos P; Kouroukis T; Adachi JD
    J Obstet Gynaecol Can; 2005 Aug; 27(8):759-64. PubMed ID: 16287007
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alendronate is more effective than etidronate for increasing bone mass in osteopenic patients with primary biliary cirrhosis.
    Guañabens N; Parés A; Ros I; Alvarez L; Pons F; Caballería L; Monegal A; Martínez de Osaba MJ; Roca M; Peris P; Rodés J
    Am J Gastroenterol; 2003 Oct; 98(10):2268-74. PubMed ID: 14572578
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Response to alendronate in osteoporosis after previous treatment with etidronate.
    Fairney A; Kyd P; Thomas E; Wilson J
    Osteoporos Int; 2000; 11(7):621-5. PubMed ID: 11069197
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of alendronate and hormone replacement therapy, alone or in combination, on bone mass in postmenopausal women with osteoporosis: a prospective, randomized study.
    Tiraş MB; Noyan V; Yildiz A; Yildirim M; Daya S
    Hum Reprod; 2000 Oct; 15(10):2087-92. PubMed ID: 11006178
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Addition of alendronate to ongoing hormone replacement therapy in the treatment of osteoporosis: a randomized, controlled clinical trial.
    Lindsay R; Cosman F; Lobo RA; Walsh BW; Harris ST; Reagan JE; Liss CL; Melton ME; Byrnes CA
    J Clin Endocrinol Metab; 1999 Sep; 84(9):3076-81. PubMed ID: 10487668
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cyclical etidronate in the treatment of postmenopausal osteoporosis: efficacy and safety after seven years of treatment.
    Miller PD; Watts NB; Licata AA; Harris ST; Genant HK; Wasnich RD; Ross PD; Jackson RD; Hoseyni MS; Schoenfeld SL; Valent DJ; Chesnut CH
    Am J Med; 1997 Dec; 103(6):468-76. PubMed ID: 9428829
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of cyclical etidronate with alfacalcidol on lumbar bone mineral density, bone resorption, and back pain in postmenopausal women with osteoporosis.
    Iwamoto J; Takeda T; Ichimura S; Matsu K; Uzawa M
    J Orthop Sci; 2003; 8(4):532-7. PubMed ID: 12898306
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of alendronate and hormone replacement therapy, alone and in combination, on bone mass and markers of bone turnover in elderly women with osteoporosis.
    Eviö S; Tiitinen A; Laitinen K; Ylikorkala O; Välimäki MJ
    J Clin Endocrinol Metab; 2004 Feb; 89(2):626-31. PubMed ID: 14764773
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of combined risedronate and hormone replacement therapies on bone mineral density in postmenopausal women.
    Harris ST; Eriksen EF; Davidson M; Ettinger MP; Moffett AH; Baylink DJ; Crusan CE; Chines AA
    J Clin Endocrinol Metab; 2001 May; 86(5):1890-7. PubMed ID: 11344179
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differences in persistence, safety and efficacy of generic and original branded once weekly bisphosphonates in patients with postmenopausal osteoporosis: 1-year results of a retrospective patient chart review analysis.
    Ringe JD; Möller G
    Rheumatol Int; 2009 Dec; 30(2):213-21. PubMed ID: 19430791
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment with alendronate plus calcium, alendronate alone, or calcium alone for postmenopausal low bone mineral density.
    Bonnick S; Broy S; Kaiser F; Teutsch C; Rosenberg E; DeLucca P; Melton M
    Curr Med Res Opin; 2007 Jun; 23(6):1341-9. PubMed ID: 17594775
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The use of etidronate and calcium versus calcium alone in the treatment of postmenopausal osteopenia: results of three years of treatment.
    Montessori ML; Scheele WH; Netelenbos JC; Kerkhoff JF; Bakker K
    Osteoporos Int; 1997; 7(1):52-8. PubMed ID: 9102064
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Etidronate and alendronate in the treatment of postmenopausal osteoporosis.
    Beauchesne MF; Miller PF
    Ann Pharmacother; 1999 May; 33(5):587-99. PubMed ID: 10369624
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.